Shares of Hims & Hers Health (NYSE: HIMS) sank 10.5% this week, according to data from S&P Global Market Intelligence. The ...

Hims & Hers Health has blazed a red-hot streak, helped by the growing popularity of weight-loss drugs. But after a massive ...

But with bitcoin plunging to less than US$79,000 at one point this week – down from a peak of more than US$109,000 in January ...

When asked whether we’ll ever find out who was behind the selloff, the CNBC TV show host stated: “Well no, and you never will ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...

Hims & Hers Health (NYSE:HIMS – Free Report) had its price objective hoisted by Leerink Partners from $24.00 to $40.00 in a report published on Tuesday,Benzinga reports. They currently have a market ...

The BUZZ NextGen AI US Sentiment Leaders Index returned 2.66% during the month of January, compared to a return of 2.78% for the S&P 500 Index during the same period.

There are cracks forming in the façade of the stock market right now. The best and brightest stocks of the last few months ...

Eli Lilly's bet on the Oscars shows the GLP-1 ad wars are heating up. - Eli Lilly. At the 2024 Academy Awards, Eli Lilly, the ...

Eli Lilly and Company, Hims & Hers Health, UnitedHealth Group, Walmart, Tempus AI, Johnson & Johnson, and Merck & Co., Inc. are the seven Medical stocks to watch today, according to MarketBeat’s stock ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.